Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism

U. Noring, U. Juul Povlsen, Daniel Casey, J. Gerlach

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

RS 86, a specific muscarinic agonist, was evaluated in a blind, placebo-controlled, single-dose trial in 10 psychiatric patients with stable tardive dyskinesia (TD). RS 86, 0.5-4 mg orally, produced no significant effects in TD, although 4 mg caused a minimal aggravation in parkinsonism. Side effects of the highest dose (4 mg) included hypersalivation (eight patients), nausea (6), sweating (3), and vomiting (3). It is concluded that treatmetn with RS 86 and probably other cholinomimetics has no or only limited beneficial effect in TD.

Original languageEnglish (US)
Pages (from-to)569-571
Number of pages3
JournalPsychopharmacology
Volume84
Issue number4
DOIs
StatePublished - Dec 1984

Fingerprint

Parkinsonian Disorders
Pharmaceutical Preparations
Sialorrhea
Muscarinic Agonists
Sweating
Nausea
Cholinergic Agents
Vomiting
Psychiatry
Placebos
2-ethyl-8-methyl-2,8-diazaspiro(4,5)decane-1,3-dione
Tardive Dyskinesia

Keywords

  • Cholinomimetics
  • Parkinsonism
  • RS 86
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. / Noring, U.; Juul Povlsen, U.; Casey, Daniel; Gerlach, J.

In: Psychopharmacology, Vol. 84, No. 4, 12.1984, p. 569-571.

Research output: Contribution to journalArticle

Noring, U. ; Juul Povlsen, U. ; Casey, Daniel ; Gerlach, J. / Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. In: Psychopharmacology. 1984 ; Vol. 84, No. 4. pp. 569-571.
@article{395edca6e1f74a72a0143e4110fc16a3,
title = "Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism",
abstract = "RS 86, a specific muscarinic agonist, was evaluated in a blind, placebo-controlled, single-dose trial in 10 psychiatric patients with stable tardive dyskinesia (TD). RS 86, 0.5-4 mg orally, produced no significant effects in TD, although 4 mg caused a minimal aggravation in parkinsonism. Side effects of the highest dose (4 mg) included hypersalivation (eight patients), nausea (6), sweating (3), and vomiting (3). It is concluded that treatmetn with RS 86 and probably other cholinomimetics has no or only limited beneficial effect in TD.",
keywords = "Cholinomimetics, Parkinsonism, RS 86, Tardive dyskinesia",
author = "U. Noring and {Juul Povlsen}, U. and Daniel Casey and J. Gerlach",
year = "1984",
month = "12",
doi = "10.1007/BF00431469",
language = "English (US)",
volume = "84",
pages = "569--571",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Effect of a cholinomimetric drug (RS 86) in tardive dyskinesia and drug-related parkinsonism

AU - Noring, U.

AU - Juul Povlsen, U.

AU - Casey, Daniel

AU - Gerlach, J.

PY - 1984/12

Y1 - 1984/12

N2 - RS 86, a specific muscarinic agonist, was evaluated in a blind, placebo-controlled, single-dose trial in 10 psychiatric patients with stable tardive dyskinesia (TD). RS 86, 0.5-4 mg orally, produced no significant effects in TD, although 4 mg caused a minimal aggravation in parkinsonism. Side effects of the highest dose (4 mg) included hypersalivation (eight patients), nausea (6), sweating (3), and vomiting (3). It is concluded that treatmetn with RS 86 and probably other cholinomimetics has no or only limited beneficial effect in TD.

AB - RS 86, a specific muscarinic agonist, was evaluated in a blind, placebo-controlled, single-dose trial in 10 psychiatric patients with stable tardive dyskinesia (TD). RS 86, 0.5-4 mg orally, produced no significant effects in TD, although 4 mg caused a minimal aggravation in parkinsonism. Side effects of the highest dose (4 mg) included hypersalivation (eight patients), nausea (6), sweating (3), and vomiting (3). It is concluded that treatmetn with RS 86 and probably other cholinomimetics has no or only limited beneficial effect in TD.

KW - Cholinomimetics

KW - Parkinsonism

KW - RS 86

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=0021647757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021647757&partnerID=8YFLogxK

U2 - 10.1007/BF00431469

DO - 10.1007/BF00431469

M3 - Article

C2 - 6152058

AN - SCOPUS:0021647757

VL - 84

SP - 569

EP - 571

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -